We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
32.00 | 1.91% | 1,705.00 | 1,701.00 | 1,701.50 | 1,718.50 | 1,673.00 | 1,685.50 | 5,853,296 | 16:35:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.21 | 70.03B |
Date | Subject | Author | Discuss |
---|---|---|---|
28/7/2021 14:20 | Here's a profound question seeking an answer. WHY DOES EVERYONE HATE THIS COMPANY? | mcflies | |
28/7/2021 14:18 | It'll be interesting to know what products will be part of the demerged group. Considering how depressed the share price have been for the last two years, I hope the sum of the parts are greater than the whole | waldo2020 | |
28/7/2021 14:15 | Difficult to say. If these results are replicated in the next few quarters then Elliot would have little leverage over what happens to GSK, that might be a factor. Sometimes good news is sold into. I focus on the numbers, and on the whole I'm happy with them. | alex1621 | |
28/7/2021 14:12 | added at 1384.2 | eurofox | |
28/7/2021 14:11 | net The BoD's should be asking themselves that question right now | mcflies | |
28/7/2021 14:10 | GlaxoSmithKline 2Q Net Profit Fell Despite Higher Sales; Backs 2021 Outlook -- UpdateSource: Dow Jones NewsBy Cecilia Butini GlaxoSmithKline PLC said Wednesday that second-quarter net profit fell from the previous year, though sales grew, and backed its outlook for the full year.The British pharmaceutical major posted net profit of 1.40 billion pounds ($1.94 billion) for the period, down from GBP2.26 billion the year prior. Adjusted earnings per share were 28.1 pence compared with 19.2 pence for the same period a year earlier.Sales came in at GBP8.09 billion, up from GBP7.62 billion for the second quarter of 2020, when both pharmaceuticals and vaccine sales were affected by the coronavirus pandemic.Pharmaceuti | spud | |
28/7/2021 14:05 | Scratch head What’s going on? | netcurtains | |
28/7/2021 14:04 | Blimy who would have thought good results would make price fall | netcurtains | |
28/7/2021 13:51 | And that's why Astra's vaccine received such poor PR. Dirty tricks department at work. | alex1621 | |
28/7/2021 13:38 | 'how come Pfizer can charge for the vaccine but others like Astra cannot?' The answer is that Astra could have charged a profit but chose not to. They didn't want to take advantage of a desperate situation. Pfizer saw it as an opportunity to make some big bucks. It's about high moral values versus greed. | mcflies | |
28/7/2021 13:36 | Based on these figures what is the current PE ratio of GSk? | netcurtains | |
28/7/2021 13:27 | Looking good for steady climb over next few weeks | netcurtains | |
28/7/2021 13:26 | This massive drop from today's highs would suggest Elliott is now out? The figures are not bad enough for them to force any changes. | mcflies | |
28/7/2021 13:20 | How come Pfizer can charge for the vaccine but others like Astra cannot? | abdullla | |
28/7/2021 13:19 | Down again. Emma speak?! | spoole5 | |
28/7/2021 13:19 | Where is Sanofi selling its vaccine? It has not been approved anywhere. So this might be payment for what has been used in the trials. | alex1621 | |
28/7/2021 13:12 | Pfizer posted some big numbers today and lifted its 2021 projection for Covid-19 vaccine revenues to $33.5bn up from the May forecast of $26bn. Pfizer said the pre-tax profit margin on the Covid-19 vaccine was in the "high-20s" in terms of percent. (France24). No wonder Pfizer has outpaced GSK in recent years. | alphorn | |
28/7/2021 13:12 | Sanofi & GSK together are partners in the sale of covid vaccine which includes supplying them with the Adjuvant . | abdullla | |
28/7/2021 13:02 | Market reaction probably not surprising. The company has signalled to the world that the group is not a sustainable model as it stands - not a particulary glowing assessment. (Continue to hold on the basis of the breakup where I expect predators). | alphorn | |
28/7/2021 12:57 | H1 included £258m for the sale of its adjuvant. Looks as though Sanofi will get the lion's share of any new vaccine. | alphorn | |
28/7/2021 12:56 | The net profit of £1.4bn is much higher than the consensus forecast of £0.6bn ... GSK delivered ahead of expectations in all areas. | alex1621 | |
28/7/2021 12:53 | Maybe that is exactly what Elliots are doing just now hence the sudden drop in share price . | abdullla | |
28/7/2021 12:50 | Lol This is obviously going to rise loads Unless I’ve missed something | netcurtains | |
28/7/2021 12:50 | What is a day release scheme ? | abdullla | |
28/7/2021 12:50 | Dig deeper, net profit falls, despite higher sales. If I were Elliott I would say ok got this wrong, dump shares move on. | montyhedge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions